Immunic, Inc. InvestorRoom

Investor Alerts

Oct 20, 2020

EIB Provides Immunic With up to €24.5 Million to Support Ongoing Development of a Potential COVID-19 Therapy

- European Investment Bank and Immunic sign a financing agreement of up to €24.5 million to support the development of Immunic's lead asset, IMU-838, in moderate COVID-19
Sep 29, 2020

Immunic, Inc. to Participate in Scientific Conferences in October
Sep 28, 2020

Immunic, Inc. Announces Results From Interim Safety Analysis and Recruitment Update From Its Ongoing Phase 2 CALVID-1 Trial of IMU-838 in Patients With Moderate COVID-19
Sep 11, 2020

Immunic, Inc. Publishes Full Unblinded Clinical Data From Phase 2 EMPhASIS Trial of IMU-838 in Patients With Relapsing-Remitting Multiple Sclerosis and Announces Poster Presentation at the MSVirtual2020

- Unblinded Subgroup Analyses Show Consistent Effect for MRI Lesion Suppression Across Different Populations -
Sep 8, 2020

Immunic, Inc. to Participate in Scientific and Investor Conferences in September
Aug 20, 2020

Immunic, Inc. Announces Dosing of First Healthy Volunteer in Phase 1 Clinical Program of IMU-856, Targeting Restoration of Intestinal Barrier Function
Aug 10, 2020

Immunic, Inc. Announces Closing of $103.5 Million Public Offering, including Full Exercise of Underwriters' Option to Purchase Additional Shares
Aug 4, 2020

Immunic, Inc. Announces Pricing of $90.0 Million Public Offering of Common Stock
Aug 3, 2020

Immunic, Inc. Announces Proposed Public Offering of 5 Million Shares of Common Stock
Aug 2, 2020

Immunic, Inc. Reports Positive Top-line Data from Phase 2 EMPhASIS Trial of IMU-838 in Patients with Relapsing-Remitting Multiple Sclerosis

- Study Meets Primary and Key Secondary Endpoints with High Statistical Significance Indicating Activity for IMU-838 in Relapsing-Remitting Multiple Sclerosis -

Show per page